Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Home Air Filtration for Traffic-Related Air Pollution (HAFTRAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04279249
Recruitment Status : Recruiting
First Posted : February 21, 2020
Last Update Posted : June 22, 2021
Sponsor:
Collaborators:
Somerville Transportation Equity Partnership, Inc.
Welcome Project Inc
Tufts University
Boston University
Olin College of Engineering
National Institute of Environmental Health Sciences (NIEHS)
Information provided by (Responsible Party):
Douglas Brugge, UConn Health

Brief Summary:

This study is a blinded randomized crossover efficacy trial (N=172 households consisting of 207 participants) of High Efficiency Particulate Air (HEPA) filtration in near-highway homes that lack mechanical air-handling systems. Households will be randomized to 30 days of either filtration or sham filtration followed by a 30 washout period with a subsequent 30-day period of the alternative assignment. Room air filters that are commercially available will be placed in the bedroom and living room of each home.

The investigators will measure UFP and PM2.5 concentrations in 20% of the homes during filtration and sham periods and assess personal exposure in a subset of participants. The investigators will also assess chemical composition of particulate air pollution in 10 homes/year for exploratory purposes that could lead to future lines of research. The primary health endpoints will be participants' hsCRP and peripheral blood pressure, measures that the investigators have used in multiple observational studies of UFP as well as in pilot filtration intervention studies. Secondary biological measures that contribute to understanding biological pathways will be IL-6 (inflammation), D-dimer (coagulation), metabolome, central pressure and arterial stiffness. The primary intention to treat analysis will compare outcomes between HEPA filtration to sham filtration. The investigators will have 80% power to detect a difference of 0.6 mg/L in change in hsCRP and a difference in reduction in systolic blood pressure of 3.5 mmHg compared to participants who receive no filtration. Having participants serve as their own controls in the within-subject comparisons of intervention effectiveness increases statistical power and eliminates the possibility of baseline imbalances in demographic and clinical characteristics. A social science evaluation will inform final adjustments to the investigators' approach at the start and also assess participant acceptance and experience with the intervention at the end. The investigators' primary innovation is that this will be the first near highway HEPA intervention trial that is large enough and careful enough to be policy-relevant.


Condition or disease Intervention/treatment Phase
Cardiovascular Risk Factor Blood Pressure Other: HEPA Air Filtration Other: Sham HEPA Air Filtration Not Applicable

Detailed Description:

Specific Aims:

Specific Aim 1: To test the effect of HEPA filtration on markers of cardiovascular risk for adults who live near urban highways. 207 participants will be enrolled in a double blind, randomized crossover trial of 30-day periods with and without filtration separated by a 30-day wash out period. The intervention will be during colder months (Oct-Mar) when ambient UFP are elevated and windows tend to be closed, thereby allowing for maximization of the exposure contrast between HEPA and sham conditions. The investigators hypothesize that the HEPA filtration intervention will be associated with indications of improved health in the primary health outcomes: blood pressure (systolic, diastolic, and pulse pressure); and hsCRP (a measure of inflammation).

Specific Aim 2: To assess whether the intervention succeeded or failed in participant homes. To determine effectiveness of the filtration intervention, the investigators will 1) measure particle pollution levels inside and outside 20% of the homes, and 2) use quantitative surveys and open-ended questions to evaluate how participants interacted with the intervention.

Specific Aim 3: To assess biomarkers that can suggest biological pathways by which filtration affects cardiovascular risk. Study participants will be measured for IL-6 (inflammation), D-dimer (coagulation), central blood pressure, and arterial stiffness (endothelial dysfunction), which constitute key steps along the presumed biological pathways. The peripheral blood plasma of all participants will also undergo metabolome analysis to provide additional evidence of biological pathways. The investigators propose this to follow on an exciting recent study that used a similar approach 24, and preliminary metabolome analysis.

Exploratory Aims: To analyze particle composition. In a subset of homes (30 homes total, 10/year), the investigators will perform detailed physical and chemical analysis of PM1 (particles <1,000 nm) to inform future work on composition-dependent health impacts and filtration effectiveness for UFP. Also in a subset of homes, assess personal exposures for 24 participants. The scientific premise is that HEPA filtration in homes without mechanical ventilation systems can reduce UFP (and overall PM) levels leading to positive changes in biomarkers. The study design and approach are rigorous, using a double blind, randomized cross over trial. The investigators will also measure objective biomarkers of risk of cardiovascular disease. The primary innovation is that this will be the first HEPA intervention trial near highways that is large enough to rule in or out efficacy of stand-alone HEPA filters from traffic pollution

Hypotheses:

  1. For Aim 1, the investigators hypothesize that the HEPA filtration intervention will be associated with statistically significant improvements of peripheral blood pressure (BP) and C-reactive protein (hsCRP).
  2. The investigators hypothesize that measures collected for Aim 3 will show that UFP is associated with antioxidant pathways, in vivo generation of reactive oxygen species, and processes critical to endothelial functions, as well as indicators of early vascular aging.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 210 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description:

This study is a randomized crossover trial, in which study participants are randomly assigned (by computer) to different arms of the study in which they receive different interventions - in this case, either the HEBO air filter or the sham filter. The two arms will run concurrently, rather than sequentially.

Primary Outcome Measures will be measured concurrently, rather than at separate time points (i.e., blood pressure and blood samples will both be taken at study onset, 30 days, 60 days and 90 days) and therefore fall within the same time points.

Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Home Air Filtration for Traffic-Related Air Pollution
Actual Study Start Date : November 30, 2020
Estimated Primary Completion Date : May 31, 2024
Estimated Study Completion Date : May 31, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Air Pollution

Arm Intervention/treatment
Active Comparator: HEPA Filtration Other: HEPA Air Filtration
2 HEPA air filters placed in home (one in bedroom, one in living room) for 30 days

Sham Comparator: Sham HEPA Filtration Other: Sham HEPA Air Filtration
2 HEPA air filter devices with filter removed placed in home (one in bedroom, one in living room) for 30 days




Primary Outcome Measures :
  1. Change in Systolic Blood Pressure at 1 Month [ Time Frame: measured at study onset and 30 days ]
    Seated blood pressure measured using ambulatory monitors

  2. Change in High Sensitivity C-Reactive Protein (hsCRP) at 1 Month [ Time Frame: blood sample taken at study onset and 30 days ]
    inflammation marker assayed from blood samples


Secondary Outcome Measures :
  1. Change in D-dimer at 1 Month [ Time Frame: blood sample taken at study onset and 30 days ]
    coagulation marker assayed from blood samples



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • residence within 200 m of interstate I-93 in Somerville
  • live at home full time
  • cognitive ability to answer questionnaires
  • able to speak English/Spanish

Exclusion Criteria:

  • in-home mechanical air handling system with forced air pushed through vents
  • smoker or lives with smoker(s)
  • history of heart attack, stroke, or other major cardiovascular outcome
  • taking anti-hypertensive or anti-inflammation medications
  • occupational or other routine high exposures (away from home) to traffic pollution
  • extensive use of candles/incense inside the home

Preferred Criteria:

  • residents of apartments with highway-facing windows and that are no more than 3 stories tall

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04279249


Contacts
Layout table for location contacts
Contact: Doug Brugge, PhD (617) 636-0236 doug.brugge@gmail.com

Locations
Layout table for location information
United States, Connecticut
UConn Health Recruiting
Farmington, Connecticut, United States, 06032
Contact: Doug Brugge, PhD    860-679-8814    doug.brugge@gmail.com   
Sponsors and Collaborators
UConn Health
Somerville Transportation Equity Partnership, Inc.
Welcome Project Inc
Tufts University
Boston University
Olin College of Engineering
National Institute of Environmental Health Sciences (NIEHS)
Investigators
Layout table for investigator information
Principal Investigator: Doug Brugge, PhD Tufts University
Layout table for additonal information
Responsible Party: Douglas Brugge, Professor, UConn Health
ClinicalTrials.gov Identifier: NCT04279249    
Other Study ID Numbers: 20-109-2
1R01ES030289 ( U.S. NIH Grant/Contract )
First Posted: February 21, 2020    Key Record Dates
Last Update Posted: June 22, 2021
Last Verified: June 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Douglas Brugge, UConn Health:
Ultrafine Particles (UFP)
HEPA
Traffic-Related Air Pollution
Air Filtration
In-home